Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook Pulls Bevacizumab BLA As Filing Falls Short

Plans To Submit Revised US Application With FDA In Q3

Executive Summary

Pinning its hopes on its proposed bevacizumab product for ophthalmic indications, Outlook Therapeutics has been told to give more information to the US FDA ahead of an approval. However, one analyst remained upbeat for the company’s prospects.

You may also be interested in...



What’s Next? Five Things To Look Out For In September

As the fourth quarter of the year nears, plenty is on the horizon for industry, with senior management shifts and a slate of high-value launches in the US and Europe.

Outlook Eyes Blockbuster-Sized Sales For An Old Eye Drug In Wet-AMD

The company is seeking FDA approval for a first-time ophthalmic formulation of bevacizumab and also refiled its BLA.

Ophthalmic Bevacizumab Sponsor Not Giving Up On EMA Rejection

The European Medicines Agency has been asked to re-examine its rejection of the EU marketing application for Ipique, which, if approved, could become the first drug containing bevacizumab to be authorized for use in neovascular (wet) macular degeneration.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel